he stark disparity in the diagnosis and treatment of Acute Lymphoblastic Leukaemia (ALL) between high-income countries (HICs) and low- and middle-income countries (LMICs) highlights a critical issue in global healthcare equity.

Congenital heart defects, or diseases, are problems with the heart’s structure that are present at birth. They may change the normal flow of blood through the heart.

We often don’t know what we are doing, but we can’t stop. Science and research never stop.

This is a series on the advances in CAR T, a remarkable immunotherapy treatment dubbed a “living drug.” This new therapy genetically modifies a patient’s cells to fight cancer, but current research efforts hope to treat autoimmune diseases, organ damage and more.